3:30 PM
Oct 30, 2018
 |  BC Extra  |  Company News

Pfizer likely to remove lid on drug price increases in January

Chairman and CEO Ian Read said Pfizer Inc. (NYSE:PFE) will likely end its agreement to defer drug price increases and return to "business as normal" by year end. Read's comments, which came during the pharma’s 3Q18 earnings conference call Tuesday, could suggest Pfizer does not expect the Trump administration to implement its drug pricing blueprint by year end, and make good on the de facto deadline Pfizer set for Trump in July.

"We did voluntarily agree to defer price increases until the blueprint was implemented or the end of this year," Read said. "We've been working...

Read the full 464 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >